BTKi bei R/R CLL und MCL
Eine globale Perspektive: Neue Daten zur BTK-Inhibitor-Therapie bei rezidivierter/refraktärer CLL und MCL in 2022

Released: January 10, 2023

Expiration: January 09, 2024

Activity

Progress
1
Course Completed

  1. Wang M, Jurczak W, Jerkeman M, et al. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract LBA7502.
  2. Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386:2482-2494.
  3. Wierda WG, Tam CS, Allan JN, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. Presented at: 2020 American Society of Hematology annual meeting; December 5-7, 2020. Abstract 123.
  4. Ghia P, Allan JN, Siddiqi T, et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. Presented at: 2021 American Society of Clinical Oncology annual meeting; June 4-8, 2021. Abstract 7501.
  5. Wierda WG, Barr PM, Siddiqi T, et al. Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract 7519.
  6. Kater A, Owen C, Moreno C, et al. Fixed duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line chronic lymphocytic leukemia: primary analysis of the phase 3 GLOW study. Presented at: 2021 European Hematology Association annual meeting; June 9-17, 2021. Abstract LB1902.
  7. Lee HJ, Choi MY, Siddiqi T, et al. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). Presented at: 2022 American Society of Clinical Oncology annual meeting; June 3-7, 2022. Abstract 7520.
  8. Mato AR, Pagel JM, Coombs CC, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract S147.
  9. Lewis K, Wang ML, Shah NN, et al. Pirtobrutinib, a highly selective, non-covalent (REVERSIBLE) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Presented at: 2022 Pan Pacific Lymphoma Conference; July 18-22, 2022.
  10. Eichhorst B, Niemann C, Kater A, et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract LB2365.
  11. Eichhorst B, Niemann C, Kater AP, et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the international intergroup GAIA (CLL13) trial. Presented at: 2021 American Society of Hematology annual meeting; December 10-14 2021. Abstract 71.
  12. Hillmen P, Pitchford A, Bloor A, et al. The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract S145.
  13. Davids M, Sharman J, Ghia P, et al. Long-term efficacy of acalabrutinib-based regimens in patients with chronic lymphocytic leukemia and higher-risk genomic features: pooled analysis of clinical trial data. Presented at: 2022 European Hematology Association annual meeting; June 9-17, 2022. Abstract P667.
  14. Kahl BS, Giannopoulos K, Jurczak W, et al. SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: 2022 Pan Pacific Lymphoma Conference; July 18-22, 2022.
  15. Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031-1043.
  16. Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease outcomes after fixed-duration ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab for first-line treatment of CLL in older adult or unfit patients: the GLOW study. Presented at: 2022 Society of Hematologic Oncology annual meeting; September 28 - October 1, 2022. Abstract CLL-106.
  17. Brown JR, Hillmen P, Eichhorst B, et al. CLL-115 first interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Clin Lymphoma Myeloma Leuk. 2022;22(suppl 1):S266.
  18. Awan FT, Addison D, Alfraih F, et al. International consensus statement on the management of cardiovascular risk of Brutons tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6:5516-5525.
  19. Munir T, Pitchford A, Bloor A, et al. Sudden or cardiac deaths on ibrutinib-based therapy were associated with a prior history of hypertension or cardiac disease and the use of ACE-inhibitors at study entry: analysis from the phase III NCRI FLAIR trial. Presented at: 2021 American Society of Hematology; December 10-14, 2021. Abstract 2636.
  20. Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2022;Epub ahead of print.
  21. Coombs CC, Pagel JM, Shah NN, et al. CLL-120 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk. 2022;22:S268.
  22. Cohen JB, Shah NN, Alencar AJ, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Presented at: 2022 Society of Hematologic Oncology annual meeting; September 28 - October 1, 2022. Abstract MCL-133.
  23. Wanchoo R, Ramirez CB, Barrientos J, et al. Renal involvement in chronic lymphocytic leukemia. Clin Kidney J. 2018;11:670-680.
  24. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Presented at: 2021 European Hematology Association Congress; June 9-17, 2021. Abstract LB1900.
  25. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7500.
  26. Rivera D, Ferrajoli A. Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies. Curr Oncol Rep. 2022;24:1003-1014.
  27. Shanafelt TD, Xang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112-120.